Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Investors Are Sitting on a Loss of 51% If They Invested Five Years Ago
Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Investors Are Sitting on a Loss of 51% If They Invested Five Years Ago
While not a mind-blowing move, it is good to see that the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) share price has gained 14% in the last three months. But that can't change the reality that over the longer term (five years), the returns have been really quite dismal. Indeed, the share price is down 52% in the period. So we're not so sure if the recent bounce should be celebrated. However, in the best case scenario (far from fait accompli), this improved performance might be sustained.
虽然这并不是一个让人惊叹的举动，但令人高兴的是，在过去的三个月中，海普瑞药品集团股份有限公司（SZSE:002399）的股价上涨了14%。但是，在较长期的时间内（五年），收益确实非常不理想。的确，在这段时间内，股价下跌了52%。所以我们不确定这次反弹是否值得庆祝。然而，在最好的情况下（远离“完成”），这种改善的表现可能会持续。虽然不完美，但很高兴看到深圳海普瑞药品集团有限公司（SZSE：002399）的股票价格在过去三个月中上涨了14％。然而，在过去五年中，股票回报率相当惨淡。股价在这段时间内下跌了52％。因此，我们不确定最近的反弹是否值得庆祝。即使如此，在最好的情况下（远离“完成”），这种改善的表现也是可持续的。在五年内，深圳海普瑞药品集团的每股收益显著下降，跌至亏损水平，股票价格也下跌。由于公司已经处于亏损的情况下，很难将每股收益的变化与股价的变化进行比较。但是，考虑到这种情况，我们通常预计会有更低的价格。
Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.
现在让我们看看这家公司的基本面，看看长期股东回报是否与基础业务的表现相匹配。
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
市场有时毫无疑问是有效的，但股票价格并不总是反映基本业务表现。一种有缺陷但合理的方法是比较每股收益（EPS）和股票价格，以评估围绕公司的情绪如何变化。
Over five years Shenzhen Hepalink Pharmaceutical Group's earnings per share dropped significantly, falling to a loss, with the share price also lower. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. But we would generally expect a lower price, given the situation.
SZSE:002399每股收益增长2024年6月8日
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下图显示了EPS随时间的变化情况（如果您单击该图像，则可以查看更多详细信息）。
This free interactive report on Shenzhen Hepalink Pharmaceutical Group's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
尽管更广泛的市场在十二个月内损失了约12％，但深圳海普瑞药品集团的股东们却损失更大，下跌了15％。即使如此，难免在下跌的市场中，有些股票会被超卖。关键是关注基本面的发展。但遗憾的是，去年的表现为该公司的糟糕运营画上了句号。五年来，股东面临着每年总亏损9％的局面。总体而言，长期的股价疲软可能是一个不好的迹象，尽管持异议的投资者可能希望研究该股，希望实现扭转。如果您想更好地了解深圳海普瑞药品集团的增长，可以查看这份更详细的历史收益、营业收入和现金流量图。
A Different Perspective
不同的观点
While the broader market lost about 12% in the twelve months, Shenzhen Hepalink Pharmaceutical Group shareholders did even worse, losing 15%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 9% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. You could get a better understanding of Shenzhen Hepalink Pharmaceutical Group's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.
虽然在过去的12个月中，整个市场大约下跌了12%，但深圳海普瑞药品集团的股东损失更大，下跌了15%。 话虽如此，一些股票在下跌的市场中被过度抛售是不可避免的。关键是要密切关注基本面发展趋势。遗憾的是，去年的表现为这家公司股东带来了糟糕的收益，五年来每年总损失达9%。总的来说，长期的股价疲软可能是一个不好的信号，虽然逆势投资者可能会希望研究这个股票，并希望出现反转。如果你想更好地了解深圳海普瑞药品集团的增长情况，可以查看这个更详细的历史收益、营业收入和现金流图表。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
当然，您可能在其他地方找到一家出色的企业进行投资。因此，请查看我们预计将实现盈利增长的公司的免费列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意，本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈？关于内容有所顾虑？直接和我们联系。或者，发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论，只使用公正的方法论，我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议，也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意，我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。